Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Up 38.5 %

Shares of EGRX opened at $0.90 on Friday. The firm has a market cap of $11.69 million, a price-to-earnings ratio of 0.76 and a beta of 0.51. The stock has a 50 day moving average of $3.42 and a 200-day moving average of $4.23. Eagle Pharmaceuticals has a 52 week low of $0.10 and a 52 week high of $14.78.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several hedge funds have recently made changes to their positions in EGRX. Headlands Technologies LLC raised its stake in shares of Eagle Pharmaceuticals by 75.7% during the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares in the last quarter. Creative Planning acquired a new position in shares of Eagle Pharmaceuticals during the 3rd quarter valued at about $59,000. Mackenzie Financial Corp bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $65,000. Finally, Fidelis Capital Partners LLC acquired a new stake in Eagle Pharmaceuticals in the 2nd quarter valued at approximately $71,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.